Sucampo Pharmaceuticals, Inc. (SCMP) Release: Swissmedic Approves AMITIZA® (Lubiprostone) For The Treatment Of Opioid-Induced Constipation
7/8/2014 6:19:12 AM
BETHESDA, Md. and ZUG, Switzerland, July 7, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has approved AMITIZA® (lubiprostone) 24 mcg for the treatment of opioid-induced constipation (OIC) in adults with chronic, non-cancer pain.
This is the second indication approved in Switzerland for AMITIZA, which is also approved for the treatment of chronic idiopathic constipation (CIC). Opioid-based medicines are widely used in the management of chronic pain, with OIC being a common adverse effect of chronic opioid use. OIC is characterized by infrequent and incomplete evacuation of stool, hard stool consistency, and straining associated with bowel movements. Scientific literature indicates that there are approximately 98,000 patients in Switzerland each year suffering from chronic non-cancer related pain1, of which approximately 62,000 require treatment for OIC2.
Help employers find you! Check out all the jobs and post your resume.
comments powered by